| Authors: |
Chugh S; Department of Radiation Oncology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India.; Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India., Panda G; Department of Medical Oncology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India.; Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India., Mokal S; Department of Pathology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India.; Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India., Jain H; Department of Medical Oncology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India.; Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India., Bagal B; Department of Medical Oncology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India.; Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India., Khanna N; Department of Radiation Oncology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India.; Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India., Epari S; Department of Clinical Research Secretariat, Tata Memorial Centre, BARC Training School Complex, Mumbai, Maharashtra, India.; Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India., Punatar S; Department of Medical Oncology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India.; Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India., Nayak L; Department of Medical Oncology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India.; Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India., Gokarn A; Department of Medical Oncology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India.; Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India., Khattry N; Department of Medical Oncology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India.; Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India., Sengar M; Department of Medical Oncology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India.; Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India., Laskar S; Department of Radiation Oncology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India.; Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India., Goda JS; Department of Radiation Oncology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India.; Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India. |
